Roche announced its acquisition of Poseida Therapeutics, a clinical-stage biopharmaceutical company, for $9.00 per share in cash at closing, representing a total equity value of approximately $1.0 billion. The transaction is expected to close in the first quarter of 2025 and is subject to customary closing conditions. Poseida's pipeline includes investigational allogeneic CAR-T cell therapies for hematologic cancers, autoimmune diseases, and solid tumors, as well as genetic medicines. The acquisition supports Roche's Pharma Strategy and allows for a range of potentially first and best-in-class therapies across oncology, immunology, and neurology.